Osaic Holdings’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-43
| Closed | -$543 | – | 7706 |
|
|
2024
Q2 | $543 | Sell |
43
-288
| -87% | -$527 | ﹤0.01% | 6964 |
|
|
2024
Q1 | $1.66K | Buy |
331
+73
| +28% | +$453 | ﹤0.01% | 6541 |
|
|
2023
Q4 | $1.85K | Sell |
258
-489
| -65% | -$4.3K | ﹤0.01% | 6564 |
|
|
2023
Q3 | $6.83K | Sell |
747
-150
| -17% | -$3.02K | ﹤0.01% | 6119 |
|
|
2023
Q2 | $18.9K | Sell |
897
-2,065
| -70% | -$63.6K | ﹤0.01% | 5601 |
|
|
2023
Q1 | $79.7K | Sell |
2,962
-1,846
| -38% | -$85.9K | ﹤0.01% | 4619 |
|
|
2022
Q4 | $169K | Sell |
4,808
-1,394
| -22% | -$167K | ﹤0.01% | 4003 |
|
|
2022
Q3 | $1.4M | Buy |
6,202
+1,420
| +30% | +$349K | ﹤0.01% | 1912 |
|
|
2022
Q2 | $904K | Buy |
4,782
+987
| +26% | +$199K | ﹤0.01% | 2378 |
|
|
2022
Q1 | $944K | Buy |
3,795
+507
| +15% | +$80.1K | ﹤0.01% | 2627 |
|
|
2021
Q4 | $512K | Sell |
3,288
-37
| -1% | -$7.16K | ﹤0.01% | 3039 |
|
|
2021
Q3 | $667K | Buy |
3,325
+333
| +11% | +$79.2K | ﹤0.01% | 2732 |
|
|
2021
Q2 | $764K | Buy |
2,992
+479
| +19% | +$120K | ﹤0.01% | 2587 |
|
|
2021
Q1 | $668K | Buy |
2,513
+650
| +35% | +$205K | ﹤0.01% | 2580 |
|
|
2020
Q4 | $687K | Buy |
1,863
+156
| +9% | +$44.7K | ﹤0.01% | 2373 |
|
|
2020
Q3 | $417K | Buy |
1,707
+1,694
| +13,031% | +$527K | ﹤0.01% | 2601 |
|
|
2020
Q2 | $4K | Buy |
+13
| New | +$3.83K | ﹤0.01% | 5600 |
|
Other funds holding EIGR
Osaic Holdings's EIGR Position: Q3 2024 in Review
Osaic Holdings sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2024, closing a stake of 43 shares — an estimated $543 sold.
Osaic Holdings first reported a position in EIGR in Q2 2020 and held it in 17 quarters. The position peaked at $1.4M in Q3 2022. 1 fund tracked by Wall St. Rank holds EIGR as of Q3 2024.
- Osaic Holdings reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- Osaic Holdings sold 43 Eiger BioPharmaceuticals, Inc. shares in Q3 2024, an estimated $543.
- Osaic Holdings first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 17 quarters.
- Osaic Holdings's Eiger BioPharmaceuticals, Inc. position peaked at $1.4M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2024.
Based on Osaic Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.